Cardiovascular diseases remain the leading cause of premature death in the developed world.
Every year, approximately three million people worldwide suffer from acute myocardial infarction (AMI), or heart attack. However, only about 47 % are diagnosed and treated.
Time is an important factor for successful treatment
The most important factor for a successful treatment of an acute myocardial infarction is time to treatment. Reality shows, however, that from onset of symptoms until treatment a lot of precious time is wasted. Delays are caused by the patient's hesitance to call for help as well as by ambulance response and journey times and slow in-hospital procedures. Thrombolytic therapy has established itself as one of the most successful modern treatment options of an acute myocardial infarction. It is easy to apply, is available in all hospitals and is considered safe in view of the serious nature of the disease.
Products
Actilyse® (alteplase)
- Thrombolytic treatment in acute myocardial infarction.
- Thrombolytic treatment in acute massive pulmonary embolism with haemodynamic instability.
Actilyse® is also registered for the indication acute ischaemic stroke which can be found under "Stroke".
Metalyse® (tenecteplase)
- Thrombolytic treatment in acute myocardial infarction.
Disclaimer:
We recognise that the Internet serves a global community. The pharmaceutical industry, however, is subject to country specific regulatory considerations, which affect the information we can provide on our products. In addition the registration status of pharmaceutical products may not be the same in different regions of the world and the approved product labels may also differ according to country specific requirements.
Therefore please check the registration details of this/these product(s) locally in order to get up-to-date information.